Voyager Pharmaceuticals

Voyager Therapeutics is a clinical-stage biotechnology company dedicated to developing transformative neurogenetic medicines for severe neurological diseases. The company's core strength lies in its proprietary TRACER™ platform, which enables the discovery of novel AAV capsids with enhanced blood-brain barrier penetration and tissue-specific targeting following intravenous administration. Voyager's pipeline features a diverse range of modalities, including gene therapies and monoclonal antibodies, targeting high-value indications such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Parkinson’s disease. Supported by significant strategic collaborations with industry leaders like Novartis, Pfizer, and Neurocrine Biosciences, Voyager is advancing its lead candidate, the anti-tau antibody VY7523, through clinical trials to address critical unmet needs in neurology.